Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Michael Patrick Miller sold 23,358 shares of the stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $3.49, for a total transaction of $81,519.42. Following the completion of the transaction, the director now directly owns 47,000 shares of the company's stock, valued at approximately $164,030. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Puma Biotechnology Trading Up 4.2 %
- 3 small-cap biotechs with potential breakthroughs in 2024
PBYI stock traded up $0.15 during midday trading on Tuesday, reaching $3.61. The company's stock had a trading volume of 148,720 shares, compared to its average volume of 505,316. Puma Biotechnology, Inc. has a 52 week low of $2.13 and a 52 week high of $7.73. The stock has a market cap of $174.14 million, a PE ratio of 10.94 and a beta of 1.09. The company has a quick ratio of 1.23, a current ratio of 1.32 and a debt-to-equity ratio of 0.90. The business's 50-day simple moving average is $3.44 and its 200-day simple moving average is $4.58.
Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01. The firm had revenue of $47.10 million for the quarter, compared to analysts' expectations of $43.99 million. Puma Biotechnology had a net margin of 4.01% and a return on equity of 18.36%. During the same period last year, the firm earned $0.05 earnings per share. As a group, sell-side analysts expect that Puma Biotechnology, Inc. will post 0.25 EPS for the current year.
Wall Street Analysts Forecast Growth
Several analysts have recently commented on the stock. HC Wainwright reissued a "buy" rating and set a $7.00 price target on shares of Puma Biotechnology in a research note on Friday, August 2nd. StockNews.com cut shares of Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a research note on Tuesday.
Check Out Our Latest Research Report on Puma Biotechnology
Institutional Investors Weigh In On Puma Biotechnology
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Great Point Partners LLC bought a new position in shares of Puma Biotechnology in the 4th quarter valued at about $4,734,000. American Century Companies Inc. grew its position in shares of Puma Biotechnology by 98.5% in the 2nd quarter. American Century Companies Inc. now owns 738,902 shares of the biopharmaceutical company's stock valued at $2,409,000 after acquiring an additional 366,653 shares during the period. Bank of New York Mellon Corp grew its position in shares of Puma Biotechnology by 63.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 308,997 shares of the biopharmaceutical company's stock valued at $1,007,000 after acquiring an additional 120,104 shares during the period. WINTON GROUP Ltd grew its position in shares of Puma Biotechnology by 59.7% in the 2nd quarter. WINTON GROUP Ltd now owns 300,599 shares of the biopharmaceutical company's stock valued at $980,000 after acquiring an additional 112,316 shares during the period. Finally, Panagora Asset Management Inc. bought a new position in shares of Puma Biotechnology in the 2nd quarter valued at about $335,000. 61.29% of the stock is currently owned by institutional investors and hedge funds.
About Puma Biotechnology
(Get Free Report)
Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Featured Articles
- Five stocks we like better than Puma Biotechnology
- Top Biotech Stocks: Exploring Innovation Opportunities
- Buy On Holdings Stock Before the Market Catches Its Second Wind?
- Stock Trading Terms - Stock Terms Every Investor Needs to Know
- 3 High-Potential Stocks That Could Turn Into Multi-Baggers
- Consumer Staples Stocks, Explained
- CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
→ What are “crypto royalties”? (From Centurion Publishing) (Ad)
Should you invest $1,000 in Puma Biotechnology right now?
Before you consider Puma Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Puma Biotechnology wasn't on the list.
While Puma Biotechnology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Beginner's Guide to Pot Stock Investing
Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.
Get This Free Report
